Tag: SII
Serum Institute to acquire 20% stake in IntegriMedical, India’s first needle-free...
The investment by SII in IntegriMedical is expected to accelerate the development and commercialization of the N-FIS technology, making it more widely accessible to patients in India and worldwide
Expert panel in favor of approval to Serum Institute’s cervical cancer...
With the government panel's backing, Serum Institute of India's Quadrivalent Human Papillomavirus vaccine (qHPV) is expected to hit the markets soon
Serum Institute to set up vaccine research centre on Symbiosis campus
The R&D centre will lead the development of new vaccines, technologies, products, and innovations in immunization practices
Biotech stalwarts to be honored with Padma Bhushan Award
Dr Cyrus Poonawalla of Serum Institute of India; and Dr Krishna Ella and Suchitra Ella of Bharat Biotech have found their place in the just released list of Padma Awards. They will be honored with Padma Bhushan for the role played by their companies during Covid-19 pandemic
Scale up the production capacity: PM Modi tells vaccine manufacturers
The prime minister, Narendra Modi interacted with vaccine manufacturers from across the country on April 20, 2021........................
ICMR backed Serum Institute’s COVISHIELD completes enrolment of Phase III clinical...
Under the strategic alliance, Indian Council for Medical Research is providing continuous support to Serum Institute of India in conducting and funding the ongoing clinical trials of COVISHIELD across 15 centres in India....................
Serum Institute to produce additional 100 million COVID-19 vaccine doses with...
The collaboration between the Serum Institute of India, Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future safe and effective COVID-19 vaccines, priced at a maximum of US$ 3 per dose, for low- and middle-income countries in 2021..................
Serum Institute seeks fast-track regulatory clearances for the COVID-19 vaccine
In a bid to generate a vaccine candidate at the earliest, the Serum Institute of India-Codagenix developed novel coronavirus virus-vaccine strain is pegged as the first in its form to progress to the pre-clinical trial phase.......................
Serum Institute develops novel coronavirus vaccine candidate, human trials in 6...
Serum Institute of India-Codagenix developed novel coronavirus virus-vaccine strain is first to progress to pre-clinical testing phase. The project has been running at an estimated cost of INR 300 crores......................
Celebrating India’s role as the vaccine hub of the world
The Serum Institute, PATH, WHO and Bill & Melinda Gates Foundation with support from the Department of Biotechnology celebrated the clinical development, manufacturing and scale-up of MenAfriVac vaccine......